Caris Life Sciences (CAI) Other Operating Expenses (2024 - 2026)

Caris Life Sciences' Other Operating Expenses history runs 3 years deep, the most recent figure standing at $106.1 million for Q1 2026.

• In Q1 2026, Other Operating Expenses rose 22.11% year-over-year to $106.1 million; the TTM figure through Mar 2026 stood at $425.6 million (up 34.22% YoY), while the FY2025 annual figure was $440.4 million, up 26.76% from the prior year.
• Other Operating Expenses for Q1 2026 stood at $106.1 million, down from $116.1 million in the prior quarter.
• The five-year high for Other Operating Expenses was $116.1 million in Q4 2025, with the low at $58.1 million in Q4 2024.
• The 3-year median for Other Operating Expenses is $90.0 million (2024), against an average of $92.8 million.
• Peak annual rise in Other Operating Expenses reached 100.03% in 2025, while the deepest fall reached 6.28% in 2025.
• Caris Life Sciences' Other Operating Expenses stood at $58.1 million in 2024, then surged by 100.03% to $116.1 million in 2025, then retreated by 8.6% to $106.1 million in 2026.
• Business Quant data shows CAI's Other Operating Expenses at $106.1 million in Q1 2026, $116.1 million in Q4 2025, and $110.6 million in Q3 2025.